pubmed tirzepatide Unveiling Tirzepatide's Therapeutic Spectrum: A Dual GIP/GLP-1 Agonist Targeting Metabolic, Neurological, and Cardiovascular Health Tirzepatide and Cancer Risk in
Description
Do not rub the injection site, as this can alter absorption and cause irritation
[DOI] [PubMed] [Google Scholar] [15].Adhikari UK, Khan R, Mikhael M, Balez R, David MA, Mahns D, et al
Author contributions XG, XH, CS, and MG conceived and designed the study
It also discusses future prospects and contributes to existing reviews by emphasizing safety, efficiency, and necessary caution in diverse contexts
It should be noted that these findings do not imply that DPP-4 inhibitors are harmful in any way or that GLP-1 drugs are definitely beneficial for brain health. Kornelius also noted that tirzepatide, a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, was not evaluated since it was approved after the beginning of the study period.
Furthermore, whereas sex-specific effects of GLP-1 have been reported for its metabolic outcomes and reward behaviors (28,29,58), research revolving GLP-1s effects on cognition and neuroprotection have been conducted mainly in males
